Search results for "Double-Blind"

showing 10 items of 662 documents

Effectiveness of high dose sublingual immunotherapy to induce a stepdown of seasonal asthma: a pilot study

2009

There is ample evidence to support the efficacy of sublingual immunotherapy (SLIT) on allergic rhinitis, while there is less solid data regarding asthma. We evaluated the effects of a high dose birch SLIT on birch-induced rhinitis and asthma in a controlled study.This double-blind, placebo-controlled, randomised, single centre trial on SLIT with birch pollen allergen extract (Stallergenes, Antony, France) included 24 patients presenting severe rhinitis and slight to moderate asthma, 14 actively and 10 placebo treated. SLIT was performed by a pre-coseasonal protocol, and was repeated for 2 years. The study plan included a selection visit, a visit at the start of the first and the second trea…

AdultMalemedicine.medical_specialtyModerate asthmaDouble-Blind Method; Humans; Immunotherapy; Seasons; Adult; Asthma; Placebos; Pilot Projects; Middle Aged; Male; Female; Drug Administration RoutesPilot ProjectsPlacebolaw.inventionPlacebosSeasonal asthmaRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumansSublingual immunotherapyPilot ProjectPlaceboAsthmabusiness.industryDrug Administration RoutesGeneral MedicineMiddle Agedmedicine.diseaseSlitAsthmaSurgerySingle centreFemaleSeasonsImmunotherapySeasonSLIT asthma allergybusinessHuman
researchProduct

Effects of moclobemide on sexual performance and nocturnal erections in psychogenic erectile dysfunction

2001

Rationale and objectives: We tested the hypothesis that the selective reversible MAO-A inhibitor moclobemide has a specific therapeutic effect on erectile dysfunction independent of its antidepressive properties. Methods: In a double-blind placebo controlled study, 12 male outpatients suffering from psychogenic erectile dysfunction without any other psychiatric disorder were investigated. Based on comprehensive diagnosis before the beginning of the study, organic factors relevant for sexual function were excluded. The treatment period was 8 weeks. Half the patients received 450 mg moclobemide during the first week, and 600 mg afterwards; the others received placebo. Apart from assessment of…

AdultMalemedicine.medical_specialtyMonoamine Oxidase InhibitorsMoclobemidePlacebo-controlled studyPlaceboDouble-Blind MethodErectile DysfunctionInternal medicineMoclobemidemedicineHumansPsychogenic diseasePharmacologyAnalysis of VariancePenile ErectionTherapeutic effectElectroencephalographyMiddle Agedmedicine.diseaseSurgeryErectile dysfunctionClinical Global ImpressionPsychologySexual functionmedicine.drugPsychopharmacology
researchProduct

A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction

1993

A double-blind parallel-group comparison study of moclobemide versus doxepin in 237 patients with major depression confirmed that moclobemide was equal in efficacy and better tolerated than doxepin. It was less sedating and caused fewer anticholinergic adverse events as measured by the UKU side-effect rating scale. Unexpectedly, moclobemide therapy more often than doxepin resulted in increased sexual desire. An exploratory analysis of UKU-measured symptoms of impaired sexual function prior to commencement of the study revealed that moclobemide more often than doxepin led to an improvement of reduced libido and impaired erection, ejaculation and orgasm. This finding is compatible with the as…

AdultMalemedicine.medical_specialtyMonoamine Oxidase InhibitorsPersonality Inventorymedicine.drug_classLibidoMoclobemideSexual BehaviorDouble-Blind MethodMoclobemidemedicineAnticholinergicHumansPharmacology (medical)PsychiatryAdverse effectDepression (differential diagnoses)Depressive DisorderDose-Response Relationship DrugMiddle AgedDoxepinPsychiatry and Mental healthSexual dysfunctionAnesthesiaBenzamidesComparison studyFemaleDoxepinmedicine.symptomPsychologymedicine.drugInternational Clinical Psychopharmacology
researchProduct

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

2009

Background: There are a few and conflicting results from randomised controlled trials (RCTs) pertaining to the influence of gender in response to currently used disease modifying drugs in Multiple Sclerosis (MS). Observational studies may be especially valuable for answering effectiveness questions in subgroups not studied in RCTs. Objective: To conduct a post-marketing analysis aimed to evaluate the gender effect on Interferon beta (IFN beta) treatment response in a cohort of relapsing (RR) MS patients. Methods: A cohort of 2570 IFN beta-treated RRMS was prospectively followed for Lip to 7 years in 15 Italian MS Centers. Cox proportional hazards regression models were used to assess gender…

AdultMalemedicine.medical_specialtyMultiple SclerosisPropensity scoreDiseasegender; interferon beta; multiple sclerosis; observational study; propensity scoreLower riskSeverity of Illness IndexMultiple sclerosis Interferon beta Gender Observational study Propensity scoreCohort StudiesDisability EvaluationYoung AdultSex Factorsgender multiple sclerosis treatment interferonDouble-Blind MethodInternal medicineObservational studymedicinegenderConfidence IntervalsOdds RatioProduct Surveillance PostmarketingHumansImmunologic FactorsMultiple sclerosiProportional Hazards ModelsExpanded Disability Status ScaleProportional hazards modelbusiness.industryMultiple sclerosisDrug Administration RoutesInterferon-betamedicine.diseaseInterferon betaSurgeryNeurologyItalyCohortPropensity score matchingRegression AnalysisSettore MED/26 - NeurologiaObservational studyFemaleNeurology (clinical)business
researchProduct

An 18-Month Follow-up, Randomized Comparison of Effectiveness and Safety of Two Hyaluronic Acid Fillers for Treatment of Moderate Nasolabial Folds

2016

Hyaluronic acid (HA) filler injection is a popular nonsurgical aesthetic procedure.To compare the effectiveness and safety of 2 hyaluronic acid fillers (HAEC and HARES) for treatment of moderate nasolabial folds (NLFs).This was an evaluator- and subject-blinded split-face study. HAEC or HARES was randomly assigned to the left or right NLF at baseline. Retreatment was performed after 9 months; follow-up extended to 18 months after baseline (9 months after retreatment). Effectiveness assessments included the Wrinkle Severity Rating Scale (WSRS) and subject preference. Safety assessments included adverse events (AEs) and local tolerability symptoms recorded by subjects during 3 weeks after tre…

AdultMalemedicine.medical_specialtyNasolabial FoldTime FactorsTreatment outcomeDermatology030230 surgerylaw.invention030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodRandomized controlled triallawDermal FillersHyaluronic acidmedicineHumansHyaluronic AcidAgedbusiness.industryFollow up studiesPatient PreferenceGeneral MedicineMiddle AgedNasolabial foldPatient preferenceSkin AgingSurgeryTreatment Outcomemedicine.anatomical_structureMulticenter studychemistryRetreatmentFemaleSurgerybusinessFollow-Up StudiesMonth follow upDermatologic Surgery
researchProduct

Mirtazapine compared with paroxetine in major depression.

2000

Background: The aim was to compare the efficacy and tolerability of mirtazapine with those of paroxetine. Method: 275 outpatients with a diagnosis of major depressive episode (DSM-IV) and a score ≥ 18 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17) were randomly assigned to 6 weeks of treatment with mirtazapine (15-45 mg/day) or paroxetine (20-40 mg/day). Efficacy was assessed by the HAM-D-17, Hamilton Rating Scale for Anxiety (HAM-A), and Clinical Global Impressions scales (Severity and Improvement), and analyses were performed on the intent-to-treat sample (127 mirtazapine-treated patients and 123 paroxetine-treated patients). Results: Mean daily doses were 32.7 mg of mirta…

AdultMalemedicine.medical_specialtyNauseaMirtazapineMirtazapineMianserinAntidepressive Agents TricyclicSeverity of Illness IndexDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineAmbulatory CareHumansPsychiatryMajor depressive episodeAgedPsychiatric Status Rating ScalesDepressive DisorderHamilton Rating Scale for DepressionMiddle AgedParoxetinePsychiatry and Mental healthParoxetineTreatment OutcomeTolerabilityAnxietyFemalemedicine.symptomPsychologymedicine.drugThe Journal of clinical psychiatry
researchProduct

TNF-α, IL-17, and IL-22 production in the rectal mucosa of nonceliac wheat sensitivity patients: role of adaptive immunity.

2020

In recent years, a new gluten- or wheat-related disease has emerged, a condition labeled "nonceliac gluten sensitivity" (NCGS) or "nonceliac wheat sensitivity" (NCWS). NCWS pathogenesis is still uncertain and attributed to very different mechanisms. We aimed to study the different T-lymphocyte subsets in the rectal mucosa of NCWS patients to demonstrate the possible contribution of adaptative immune response. Twelve patients (11 women, 1 man, age range 23-61 yr, median 32 yr) with a definitive diagnosis of NCWS were recruited at random for the present study. They underwent rectal endoscopy with multiple mucosal biopsies at the end of a double-blind placebo-controlled (DBPC) wheat challenge …

AdultMalemedicine.medical_specialtyNecrosisSettore MED/09 - Medicina InternaPhysiologynon-celiac wheat sensitivityBiopsyTNFWheat HypersensitivityAdaptive ImmunityGastroenterologyInterleukin 22PathogenesisYoung AdultImmune systemDouble-Blind MethodAntigens CDPhysiology (medical)Internal medicinemedicineIL-22HumansMucous MembraneHepatologybusiness.industryTumor Necrosis Factor-alphaInterleukinsInterleukin-17GastroenterologyRectumColonoscopyMiddle AgedAcquired immune systemLymphocyte SubsetsIL-17Tumor necrosis factor alphaFemaleInterleukin 17medicine.symptombusinessCD8American journal of physiology. Gastrointestinal and liver physiology
researchProduct

Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, par…

2011

Medication-overuse headache (MOH) represents a severely disabling condition, with a low response to prophylactic treatments. Recently, consistent evidences have emerged in favor of botulinum toxin type-A (onabotulinum toxin A) as prophylactic treatment in chronic migraine. In a 12-week double-blind, parallel group, placebo-controlled study, we tested the efficacy and safety of onabotulinum toxin A as prophylactic treatment for MOH. A total of 68 patients were randomized (1:1) to onabotulinum toxin A (n = 33) or placebo (n = 35) treatment and received 16 intramuscular injections. The primary efficacy end point was mean change from baseline in the frequency of headache days for the 28-day per…

AdultMalemedicine.medical_specialtyNeurologyOriginalPain medicineClinical NeurologyBotulinum toxin type-APlaceboInjections Intramuscularlaw.inventionChronic MigraineRandomized controlled trialDouble-Blind MethodlawmedicineHumansBotulinum Toxins Type AAdverse effectMuscle SkeletalBotulinum toxin type-A; Medication-overuse headache; Prophylactic treatment; Migraine; Pericranial muscle tendernessMigraineAgedAnalgesicsbusiness.industrySkullHeadacheGeneral MedicineMiddle Agedmedicine.diseaseBotulinum toxinMedication-overuse headacheAnesthesiology and Pain MedicinePericranial muscle tendernessMigraineNeuromuscular AgentsAnesthesiaSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessProphylactic treatmentmedicine.drugThe journal of headache and pain
researchProduct

Abdominal Ultrasound Does Not Reveal Significant Alterations in Patients With Nonceliac Wheat Sensitivity

2017

Abstract GOALS: The goal of this study was (A) to evaluate abdominal ultrasound signs in nonceliac wheat sensitivity (NCWS) patients for features useful in diagnosis and (B) to compare these aspects with those of celiac patients to assess whether ultrasound can be useful in the differential diagnosis between NCWS and celiac disease (CD). BACKGROUND: NCWS diagnosis is difficult as no biomarkers of this condition have as yet been identified. In CD ultrasound aspects have been identified that have a good diagnostic accuracy. STUDY: We prospectively recruited 45 NCWS patients (11 males, 34 females; mean age 35.7 y). Three control groups were included: (A) 99 age-matched CD patients; (B) 18 pati…

AdultMalemedicine.medical_specialtyNon-Celiac Wheat sensitivity Celiac Disease Abdominal Ultrasound Seronegative celiac disease Double-blind placebo-controlled challengeSettore MED/09 - Medicina InternaGlutensWheat HypersensitivityGastroenterology030218 nuclear medicine & medical imagingDiagnosis DifferentialIrritable Bowel SyndromeDiet Gluten-FreeYoung Adult03 medical and health sciences0302 clinical medicineDouble-Blind MethodInternal medicineElimination dietAbdomenAscitesmedicineHumansMesenteric lymph nodesProspective StudiesProspective cohort studyIrritable bowel syndromeUltrasonographybusiness.industryUltrasoundGastroenterologyMiddle Agedmedicine.diseaseCeliac Diseasemedicine.anatomical_structureFemale030211 gastroenterology & hepatologyGluten freemedicine.symptomDifferential diagnosisbusiness
researchProduct

Alpha lipoic acid efficacy in burning mouth syndrome: a controlled clinical trial

2014

Background A double-blind placebo-controlled trial was conducted in order to evaluate the efficacy of alpha lipoic acid (ALA) and determine the statistical significance of the outcome variables. Burning mouth syndrome (BMS) is defined as an oral burning sensation in the absence of clinical signs which could justify the syndrome. Recent studies suggest the existence of neurological factors as a possible cause of the disease. Material and Methods 60 patients with BMS, in two groups: case group with 600 mg/day and placebo as control group; with follow up of 2 months. Results 64% of ALA patients reported some level of improvement, with a level of maintenance of 68.75% one month after treatment.…

AdultMalemedicine.medical_specialtyPathologyOdontologíaBurning Mouth SyndromeDiseasePlaceboPlacebo groupGastroenterologyAntioxidantslaw.inventionDouble-Blind MethodRandomized controlled triallawInternal medicineStatistical significancemedicineHumansGeneral DentistryAgedBurning SensationAged 80 and overOral Medicine and PathologyThioctic Acidbusiness.industryResearchMiddle AgedBurning mouth syndrome:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludClinical trialTreatment OutcomeOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASFemaleSurgerymedicine.symptombusiness
researchProduct